Hammerhead ribozymes: Biochemical and chemical considerations

Current Opinion in Molecular Therapeutics

Volumn 2, Issue 3, 2000, Pages 272-281

  Goodchild, John ^a  

^a UNIVERSITY OF CENTRAL FLORIDA   (United States)

Author keywords

Chemical modification; Facilitator oligonucleotide; Hammerhead; MRNA knockout; Nuclease resistance; Ribozyme

Indexed keywords

RIBOZYME;

CHEMICAL MODIFICATION; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; PROTEIN SECONDARY STRUCTURE; REVIEW;

ANIMALS; BASE SEQUENCE; BINDING SITES; HUMANS; KINETICS; NUCLEIC ACID CONFORMATION; RNA, ANTISENSE; RNA, CATALYTIC; THERMODYNAMICS;

SPHYRNA;

EID: 0033947611     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. The RNA World. Gesteland R, Atkins JF (Eds), Cold Spring Harbor Laboratory Press, NY, USA (1993).
2. Usman N, McSwiggen JA: Catalytic RNA (ribozymes) as drugs. Annu Rep Med Chem (1995) 30:285-294.
3. Christoffersen RE, Marr JJ: Ribozymes as human therapeutic agents. J Med Chem (1995) 38:2023-2037.
4. Hertel KJ, Pardi A, Uhlenbeck OC, Koizumi M, Ohtsuka E, Uesugi S, Cedergren R, Eckstein F, Gerlach WL, Hodgson R, Symons RH: Numbering system for the hammerhead. Nucleic Acids Res (1992) 20:3252.
5. Ruffner DE, Stormo GD, Uhlenbeck OC: Sequence requirements of the hammerhead RNA self-cleavage reaction. Biochemistry (1990) 29:10695-10702.
6. Uhlenbeck OC: A small catalytic oligoribonucleotide. Nature (1987) 328:596-600.
7. Haseloff J, Gerlach WL: Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature (1988) 334:585-591.
8. Perriman R, Delves AG, Gerlach WL: Extended target-site specificity for a hammerhead ribozyme. Gene (1992) 113:157-163.
9. Shimayama T, Nishikawa S, Taira K: Generality of the NUX rule: Kinetic analysis of the results of systematic mutations in the trinucleotide at the cleavage site of hammerhead ribozymes. Biochemistry (1995) 34:3649-3654.
10. Zoumadakis M, Tabler M: Comparative analysis of cleavage rates after systematic permutation of the NUX consensus target motif for hammerhead ribozymes. Nucleic Acids Res (1995) 23:1192-1196.
11. Simorre JP, Legauit P, Baidya N, Uhlenbeck OC, Maloney L, Wincott F, Usman N, Beigelman L, Pardi A: Structural variation induced by different nucleotides at the cleavage site of the hammerhead ribozyme. Biochemistry (1998) 37:4034-4044.
12. Baidya N, Ammons GE, Matulic-Adamic J, Karpeisky AM, Beigelman L, Uhlenbeck OC: Functional groups on the cleavage site pyrimidine nucleotide are required for stabilization of the hammerhead transition state. RNA (1997) 3:1135-1142.
13. Baidya N, Uhlenbeck OC: A kinetic and thermodynamic analysis of cleavage site mutations in the hammerhead ribozyme. Biochemistry (1997) 36:1108-1114.
14. Propsting MJ, Blaschke M, Haas RE, Genschel J, Hedrich HJ, Manns MP, Schmidt HHJ: Inosine(15.1) hammerhead ribozymes for targeting the transthyretin-30 mutation. Biochem Biophys Res Commun (1999) 260:313-317.
15. Ludwig J, Blaschke M, Sproat BS: Extending the cleavage rules for the hammerhead ribozyme: mutating adenosine(15.1) to inosine(15.1) changes the cleavage site specificity from (NUH17)-U-16.2-H-16.1 to (NCH17)-C-16.2-H-16.1. Nucleic Acids Res (1998) 26:2279-2285.
16. Fedor MJ, Uhlenbeck OC: Kinetics of intermolecular cleavage by hammerhead ribozymes. Biochemistry (1992) 31:12042-12054.
17. Hammann C, Hormes R, Sczakiel G, Tabler M: A spermidine-induced conformational change of long-armed hammerhead ribozymes: Ionic requirements for fast cleavage kinetics. Nucleic Acids Res (1997) 25:4715-4722.
18. Dahm SC, Derrick WB, Uhlenbeck OC: Evidence for the role of solvated metal hydroxide in the hammerhead cleavage mechanism. Biochemistry (1993) 32:13040-13045.
19. Bassi GS, Murchie AIH, Lilley DMJ: The ion-induced folding of the hammerhead ribozyme: Core sequence changes that perturb folding into the active conformation. RNA (1996) 2:756-768.
20. Bassi GS, Murchie AIH, Walter F, Clegg RM, Lilley DMJ: Ion-induced folding of the hammerhead ribozyme: A fluorescence resonance energy transfer study. EMBO J (1997) 16:7481-7489.
21. Orita M, Vinayak R, Andrus A, Warashina M, Chiba A, Kaniwa H, Nishikawa F, Nishikawa S, Taira K: Magnesium-mediated conversion of an inactive form of a hammerhead ribozyme to an active complex with its substrate - An investigation by NMR spectroscopy. J Biol Chem (1996) 271:9447-9454.
22. Perkins TA, Wolf DE, Goodchild J: Fluorescence resonance energy transfer analysis of ribozyme kinetics reveals the mode of action of a facilitator oligonucleotide. Biochemistry (1996) 35:16370-16377.
23. Dahm SC, Uhlenbeck OC: Characterization of deoxy-and ribo-containing oligonucleotide substrates in the hammerhead self-cleavage reaction. Biochimie (1990) 72:819-823.
24. Stage-Zimmermann TK, Uhlenbeck OC: Hammerhead ribozyme kinetics. RAM (1998) 4:875-889.
25. Goodchild J, Kohli V: Ribozymes that cleave an RNA sequence from human immunodeficiency virus: The effect of flanking sequence on rate. Arch Biochem Biophys (1991) 284:386-391.
26. Bertrand E, Pictet R, Grange T: Can hammerhead ribozymes be efficient tools to inactivate gene function. Nucleic Acids Res (1994) 22:293-300.
27. Nesbitt S, Goodchild J: Further studies on the use of oligonucleotide facilitators to increase ribozyme turnover. Antisense Res Dev (1994) 4:243-249.
28. Heidenreich O, Eckstein F: Hammerhead ribozyme-mediated cleavage of the long terminal repeat RNA of human immunodeficiency virus type 1. J Biol Chem (1992) 267:1904-1909.
29. Takagi Y, Taira K: Temperature-dependent change in the rate-determining step in a reaction catalyzed by a hammerhead ribozyme. FEBS Lett (1995) 361:273-276.
30. Koizumi M, Ohta T, Komatsu Y, Ohtsuka E: Cleavage of short RNAs containing higher ordered structures by hammerhead ribozymes. Nucleosides Nucleotides (1996) 15:505-517.
31. Hendrix C, Anne J, Joris B, Vanaerschot A, Herdewijn P: Selection of hammerhead ribozymes for optimum cleavage of interleukin 6 mRNA. Biochem J (1996) 314 (Part 2):655-661.
32. Tabler M, Homann M, Tzortzakaki S, Sczakiel G: A three-nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: Advantages of an asymmetric design. Nucleic Acids Res (1994) 22:3958-3965.
33. Holm PS, Dietel M, Krupp G: Similar cleavage efficiencies of an oligoribonucleotide substrate and an mdr1 mRNA segment by a hammerhead ribozyme. Gene (1995) 167:221-225.
34. Xing Z, Whitton JL: Ribozymes which cleave arenavirus RNAs: Identification of susceptible target sites and inhibition by target site secondary structure. J. J Gen Virol (1992) 66:1361-1369.
35. Clouet-D'Orval B, Uhlenbeck OC: Kinetic characterization of two I/II format hammerhead ribozymes. RNA (1996) 2:483-491.
36. Herschlag D: Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: More isn't always better. Proc Natl Acad Sci USA (1991) 88:6921-6925.
37. Phylactou LA, Tsipouras P, Kilpatrick MW: Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target Biochem Biophys Res Commun (1998) 249:804-810.
38. Hertel KJ, Herschlag D, Uhlenbeck OC: Specificity of hammerhead ribozyme cleavage. EMBO J (1996) 15:3751-3757.
39. Hertel KJ, Uhlenbeck OC: The internal equilibrium of the hammerhead ribozyme reaction. Biochemistry (1995) 34:1744-1749.
40. Long DM, Lariviere FJ, Uhlenbeck OC: Divalent metal ions and the internal equilibrium of the hammerhead ribozyme. Biochemistry (1995) 34:14435-14440.
41. Pley H, Flaherty KM, McKay DB: Three-dimensional structure of a hammerhead ribozyme. Nature (1994) 372:68-74.
42. Scott WG, Finch JT, Grenfell R, Fogg J, Smith T, Gait MJ, Klug A: Rapid crystallization of chemically synthesized hammerhead RNAs using a double screening procedure. J Mol Biol (1995) 250:327-332.
43. Sczakiel G: The three-dimensional structure of hammerhead ribozymes. Angew Chem Int Ed Eng (1995) 34:643-645.
44. Scott WG, Finch JT, Klug A: The crystal structure of an all-RNA hammerhead ribozyme: A proposed mechanism for RNA catalytic cleavage. Cell (1995) 81:991-1002.
45. Mei B-Y, Kaaret TW, Bruice TC: A computational approach to the mechanism of self-cleavage of hammerhead RNA. Proc Natl Acad Sci USA (1989) 86:9727-9731.
46. Setlik RF, Shibata M, Sarma RH, Sarma MH, Kazim AL, Omstein RL, Tomasi TB, Rein R: Modeling of a possible conformational change associated with the catalytic mechanism in the hammerhead ribozyme. J Biomol Struct Dyn (1995) 13:515-522.
47. Scott WG, Murray JB, Arnold JRP, Stoddard BL, Klug A: Capturing the structure of a catalytic RNA intermediate: The hammerhead ribozyme. Science (1996) 274:2065-2069.
48. Murray JB, Terwey DP, Maloney L, Karpeisky A, Usman N, Beigelman L, Scott WG: The structural basis of hammerhead ribozyme self-cleavage. Cell (1998) 92:665-673.
49. Goodchild J: Enhancement of ribozyme catalytic activity by a contiguous oligodeoxynucleotide (facilitator) and by 2′-O-methylation. Nucleic Acids Res (1992) 20:4607-4612.
50. Denman RB: Cleavage of full-length β-APP messenger RNA by hammerhead ribozymes. Nucleic Acids Res (1993) 21:4119-4125.
51. Denman RB: Facilitator oligonucleotides increase ribozyme RNA-binding to full-length RNA substrates in vitro. FEBS Lett (1996) 382:116-120.
52. Jankowsky E, Schwenzer B: Oligonucleotide facilitators enable a hammerhead ribozyme to cleave long RNA substrates with multiple-turnover activity. Eur J Biochem (1998) 254:129-134.
53. Jankowsky E, Schwenzer B: Efficient improvement of hammerhead ribozyme mediated cleavage of long substrates by oligonucleotide facilitators. Biochemistry (1996) 35:15313-15321.
54. Jankowsky E, Schwenzer B: Oligonucleotide facilitators may inhibit or activate a hammerhead ribozyme. Nucleic Acids Res (1996) 24:423-429.
55. Sioud M, Jespersen L: Enhancement of hammerhead ribozyme catalysis by glyceraldehyde-3-phosphate dehydrogenase. J Mol Biol (1996) 257:775-789.
56. Tsuchihashi Z, Khosla M, Herschlag D: Protein enhancement of hammerhead ribozyme catalysis. Science (1993) 262:99-102.
57. Bertrand EL, Rossi JJ: Facilitation of hammerhead ribozyme catalysis by the nucleocapsid protein of HIV-1 and the heterogeneous nuclear ribonucleoprotein A1. EMBO J (1994) 13:2904-2912.
58. Müller G, Strack B, Dannull J, Sproat BS, Surovoy A, Jung G, Moelling K: Amino acid requirements of the nucleocapsid protein of HIV-1 for increasing catalytic activity of a Ki-ras ribozyme in vitro. J Mol Biol (1994) 242:422-429.
59. Mahieu M, Hendrix C, Ooms J, Herdewijn P, Content J: In vitro NCp7 enhancement of ribozyme-mediated cleavage of full-length human IL-6 mRNA. Biochem Biophys Res Commun (1995) 214:36-43.
60. Ventura M, Wang P, Franck N, Saragosti S: Ribozyme targeting of HIV-1 LTR. Biochem Biophys Res Commun. (1994) 203:889-898.
61. Sczakiel G, Goody RS: Antisense principle or ribozyme action? Biological Chemistry Hoppe-Seyler (1994) 375:745-746.
62. Kashani-Sabet M, Funato T, Tone T, Jiao L, Wang W, Yoshida E, Kashfinn BI, Shitara T, Wu AM, Moreno JG, Traweek ST, Ahlering TE, Scanlon KJ: Reversal of the malignant phenotype by an anti-ras ribozyme. Antisense Res Dev (1992) 2:3-15.
63. Feng M, Cabrera G, Deshane J, Scanlon KJ, Curiel DT: Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res (1995) 55:2024-2028.
64. Koizumi M, Hayase Y, Iwai S, Kamiya H, Inoue H, Ohtsuka E: Design of RNA enzymes distinguishing a single base mutation in RNA. Nucleic Acids Res (1989) 17:7059-7071.
65. Koizumi M, Kamiya H, Ohtsuka E: Ribozymes designed to inhibit transformation of NIH3T3 cells by the activated c-Haras gene. Gene (1992) 117:179-184.
66. Krieg AM, Matson S, Rsher E: Oligodeoxynucleotide modifications determine the magnitude of B-cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Dev (1996) 6:133-139.
67. Nedbal W, Sczakiel G: Hammerhead ribozyme activity in the presence of low molecular weight cellular extract Antisense Nucleic Acid Drug Dev (1997) 7:585-589.
68. Olsen DB, Benseler F, Aurup H, Pieken WA, Eckstein F: Study of a hammerhead ribozyme containing 2′-modified adenosine residues. Biochemistry (1991) 30:9735-9741.
69. Wang JY, Qiu L, Drlica K: Hammerhead ribozyme structure probed by cell extracts. Gene(1996) 181:117-120.
70. Qiu L, Moreira A, Kaplan G, Levitz R, Wang JY, Xu C, Drlica K: Degradation of hammerhead ribozymes by human ribonucleases. Mol Gen Genet (1998) 258:352-362.
71. Beigelman L, McSwiggen JA, Draper KG, Gonzalez C, Jensen K, Karpeisky AM, Modak AS, Matulic-Adamic J, Direnzo AB, Haeberli P, Sweedler D, Tracz D, Grimm S, Wincott FE, Thackray VG, Usman N: Chemical modification of hammerhead ribozymes - Catalytic activity and nuclease resistance. J Biol Chem (1995) 270:25702-25708.
72. Heidenreich O, Xu X, Swiderski P, Rossi JJ, Nerenberg M: Influence of chemical modifications on ribozyme activity and stability in nuclei suspension. Antisense Res Dev (1995).
73. Heidenreich O, Xu X, Swiderski P, Rossi JJ, Nerenberg M: Correlation of activity with stability of chemically modified ribozymes in nuclei suspension. Antisense Nucleic Acid Drug Dev (1996) 6:111 -118.
74. Jarvis TC, Wincott FE, Alby LJ, McSwiggen JA, Beigelman L, Gustofson J, DiRenzo A, Levy K, Arthur M, Matulic-Adamic J, Karpeisky A, Gonzalez C, Woolf TM, Usman N, Stinchcomb DT: Optimizing the cell efficacy of synthetic ribozymes - Site selection and chemical modifications of ribozymes targeting the proto-oncogene c-myb. J Biol Chem (1996) 271:29107-29112.
75. Pieken WA, Olsen DB, Benseler F, Aurup H, Eckstein F: Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes. Science (1991) 252:314-317.
76. Scherr M, Klebba C, Haner R, Ganser A, Engels JW: Synthesis and properties of hammerhead ribozymes stabilized against nucleases by different 2′-modifications: Methoxyethoxy-, fluoro-and amino groups. Bioorg Med Chem Lett (1997) 7:1791-1796.
77. Engels JW, Scherr M, Ganser A, Grez M, Wittmann V: Modified hammerhead ribozymes as potential therapeutics. Nucleosides Nucleotides (1998) 17:1685-1696.
78. Yang J-H, Usman N, Chartrand P, Cedergren R: Minimum ribonucleotide requirement for catalysis by the RNA hammerhead domain. Biochemistry (1992) 31:5005-5009.
79. Paolella G, Sproat BS, Lamond AI: Nuclease resistant ribozymes with high catalytic activity. EMBO J (1992) 11:1913-1919.
80. Beigelman L, Karpeisky A, Matulicadamic J, Haeberli P, Sweedler D, Usman N: Synthesis of 2′-modified nucleotides and their incorporation into hammerhead ribozymes. Nucleic Acids Res (1995) 23:4434-4442.
81. Usman N, Beigelman L, McSwiggen JA: Hammerhead ribozyme engineering. Curr Opin Struct Biol (1996) 6:527-533.
82. Scherr M, Grez R, Ganser A, Engels JW: Specific hammerhead ribozyme-mediated cleavage of mutant N-ras mRNA in vitro and ex vivo. Oligoribonucleotides as therapeutic agents. J Biol Chem (1997) 272:14304-14313.
83. Sioud M, Sorensen DR: A nuclease-resistant protein kinase C a ribozyme blocks glioma cell growth. Nature Biotechnol (1998) 16:556-561.
84. Leirdal M, Sioud M: High cleavage activity and stability of hammerhead ribozymes with a uniform 2′-amino pyrimidine modification. Biochem Biophys Res Commun (1998) 250:171-174.
85. Prasmickaite L, Hogsel A, Maelandsmo G, Berg K, Goodchild J, Perkins T, Fodstad O, Hovig E: Intracellular metabolism of a 2′-O-methyl-stabilized ribozyme after uptake by DOTAP transfection or as free ribozyme. A study by capillary electrophoresis. Nucleic Acids Res (1998) 26:4241-4248.
86. Sioud M, Natvig JB, Forre O: Preformed ribozyme destroys tumor necrosis factor mRNA in human cells. J Mol Biol (1992) 223:831-835.
87. Taylor NR, Kaplan BE, Swiderski P, Li HT, Rossi JJ: Chimeric DNA-RNA hammerhead ribozymes have enhanced in vitro catalytic efficiency and increased stability In vivo. Nucleic Acids Res (1992) 20:4559-4565.
88. Snyder DS, Wu YP, Wang JL, Rossi JJ, Swiderski P, Kaplan BE, Forman SJ: Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood (1993) 82:600-605.
89. Lange W, Cantin EM, Finke J, Dolken G: In vitro and in vivo effects of synthetic ribozymes targeted against bcr/abl messenger RNA. Leukemia (1993) 7:1786-1794.
90. Kariko K, Megyeri K, Xiao Q, Bamathan ES: Lipofectin-aided cell delivery of ribozyme targeted to human urokinase receptor mRNA. FEBS Lett (1994) 352:41-44.
91. Lange W, Daskalakis M, Finke J, Dolken G: Comparison of different ribozymes for efficient and specific cleavage of bcr/abl related mRNAs. FEBS Lett (1994) 338:175-178.
92. Gu J-L, Veerapanane D, Rossi J, Natarajan R, Thomas L, Nadler J: Ribozyme-mediated inhibition of expression of leukocytetype 12-lipoxygnease in porcine aortic vascular smooth muscle cells. Circulation Res (1995) 77:14-20.
93. Parry TJ, Cushman C, Gallegos AM, Agrawal AB, Richardson M, Andrews LE, Maloney L, Mokler VR, Wincott FE, Pavco PA: Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA. Nucleic Acids Res (1999) 27:2569-2577.
94. Gu JL, Nadler J, Rossi J: Use of a hammerhead ribozyme with cationic liposomes to reduce leukocyte type 12-lipoxygenase expression in vascular smooth muscle. Mol Cell Biochem (1997) 172:47-57.
95. Kitajima I, Hanyu N, Soejima Y, Hirano R, Arahira S, Yamaoka S, Yamada R, Maruyama I, Kaneda Y: Efficient transfer of synthetic ribozymes into cells using hemagglutinating virus of Japan (HVJ)-cationic liposomes - Application for ribozymes that target human T-cell leukemia virus type I tax/rex mRNA. J Biol Chem (1997) 272:27099-27106.
96. Sioud M: Ribozyme modulation of lipopolysaccharide-induced tumor necrosis factor-α production by peritoneal cells in vitro and in vivo. Eur J Immunol (1996) 26:1026-1031.
97. Konopka K, Rossi JJ, Swiderski P, Slepushkin VA, Duzgunes N: Delivery of an anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes. Biochim Biophys Acta Biomembr (1998) 1372:55-68.
98. Masuda Y, Kobayashi H, Holland JF, Ohnuma T: Reversal of multidrug resistance by a liposome-MDR1 ribozyme complex. Cancer Chemother Pharmacol (1998) 42:9-16.
99. Lyngstadaas SP, Risnes S, Sproat BS, Thrane PS, Prydz HP: A synthetic, chemically modified ribozyme eliminates amelogenin, the major translation product in developing mouse enamel in vivo. EMBO J (1995) 14:5224-5229.
100. Flory CM, Pavco PA, Jarvis TC, Lesch ME, Wincott FE, Beigelman L, Hunt SW, Schrier DJ: Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint. Proc Natl Acad Sci USA (1996) 93:754-758.
101. Jarvis TC, Alby LJ, Beaudry AA, Wincott FE, Beigelman L, McSwiggen JA, Usman N, Stinchcomb DT: Inhibition of vascular smooth muscle cell proliferation by ribozymes that cleave c-myb mRNA. RNA (1996) 2:419-428.
102. Flores MVC, Atkins D, Wade D, O'Sullivan WJ, Stewart TS: Inhibition of Plasmodium falciparum proliferation in vitro by ribozymes. J Biol Chem (1997) 272:16940-16945.
103. Denman RB: Ribozyme and antisense RNAs inhibit coupled transcription translation by binding to rabbit polyribosomes. Biochem Biophys Res Commun (1997) 230:226-231.